

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/
Form 8-K
October 10, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 5, 2002

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

State or other jurisdiction of incorporation: Delaware

Commission File No.: 333-45241

I.R.S. Employer Identification No.: 22-3542636

Address of principal executive offices 165 Ludlow Avenue
Northvale, New Jersey

Registrant's telephone number, including area code: 201 750-2646

Item 5. Other Events

On October 5, 2002, the consent solicitation of Harris Freedman, Sharon Will and Michael H. Freedman, and their affiliates ended without sufficient consents being obtained to replace independent directors of Elite Pharmaceuticals, Inc. The press release issued October 9, 2002 by Elite Pharmaceuticals, Inc. regarding such outcome is attached hereto as Exhibit 99 and is incorporated herein.

Item 7. Exhibits

(c) Exhibit 99. Press release of Elite Pharmaceuticals, Inc. dated October 9, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

Date: October 10, 2002

ELITE PHARMACEUTICALS, INC.

By: /s/ Atul M. Mehta

Atul M. Mehta
President